Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

Tristan Manalac, 16 Dec 2017
Methylphenidates, but not amphetamines, when taken during the first trimester of pregnancy, slightly increase the risk of cardiac congenital malformations, a recent study has shown.
Saras Ramiya, 12 Aug 2016
Patient-centred care is the focus of the upcoming International World Pharmacists' Day Convention, which is coorganized by the Malaysian Community Pharmacy Guild (MCPG) and the Malaysian Pharmaceutical Society (MPS) in September.
Pearl Toh, Yesterday
The survival benefits conferred by blood pressure (BP) and lipid-lowering medications persist even after more than a decade following the end of the original trial, according to results from the ASCOT* Legacy study.

R2CHOP reduces CNS relapse in diffuse large B-cell lymphoma

10 Jul 2018
Kanker darah, seperti leukemia, Hodgkin lymphona, non-Hodgkin lymphoma dan multiple myeloma

Adding lenalidomide to the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R2CHOP) frontline therapy for diffuse large B-cell lymphoma (DLBCL) reduces the rate of central nervous system (CNS) relapse, according to a recent study.

Accessing records from two R2CHOP trials, researchers grouped 136 DLBCL patients into three groups of low (n=14; median age 56.5 years), intermediate (n=97; median age 69 years) and high (n=25; median age 69 years) risk of CNS relapse. The Kaplan-Meier method was used to estimate relapse rates, which were then compared among groups.

Only one of the participants developed isolated CNS relapse, yielding an incidence rate of 0.7 percent. The time to relapse was 10 months and the event occurred 6 months after a complete treatment response was achieved. The participant belonged to the high-risk group.

The Kaplan-Meier estimate for the 2-year relapse rate was 0.9 percent for the entire R2CHOP cohort. The corresponding values for the low-, intermediate- and high-risk groups were 0, 0 and 5.0 percent. Compared with database patients treated with R-CHOP only, the 2-year CNS relapse rate for R2CHOP was lower (0.9 percent vs 1.8 percent).

The same was true for the low- (0 percent vs 1.4 percent) and intermediate- (0 percent vs 2.2 percent) risk groups, but not the high-risk patients (5.0 percent vs 1.1 percent).

The findings support further studies on the value of lenalidomide in decreasing CNS relapse in DLBCL patients, said researchers, noting that involving clinical and molecular factors in patient risk stratification may be an effective approach.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

Tristan Manalac, 16 Dec 2017
Methylphenidates, but not amphetamines, when taken during the first trimester of pregnancy, slightly increase the risk of cardiac congenital malformations, a recent study has shown.
Saras Ramiya, 12 Aug 2016
Patient-centred care is the focus of the upcoming International World Pharmacists' Day Convention, which is coorganized by the Malaysian Community Pharmacy Guild (MCPG) and the Malaysian Pharmaceutical Society (MPS) in September.
Pearl Toh, Yesterday
The survival benefits conferred by blood pressure (BP) and lipid-lowering medications persist even after more than a decade following the end of the original trial, according to results from the ASCOT* Legacy study.